search
Back to results

huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

Primary Purpose

Pancreatic Cancer, Serous Ovarian Cancer

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
VCN-01
huCART-meso Cells
Sponsored by
University of Pennsylvania
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pancreatic Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients with one of the following diagnoses:

    1. Histologically confirmed unresectable or metastatic pancreatic adenocarcinoma; OR
    2. Persistent or recurrent serous epithelial ovarian cancer
  2. Progression or intolerance to at least one prior standard of care chemotherapy for advanced stage disease.
  3. Subjects must have measurable disease as defined by RECIST 1.1 criteria.
  4. Patients ≥ 18 years of age.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  6. Adequate organ and bone marrow function defined as:

    1. Hemoglobin ≥ 9 g/dL
    2. Platelets ≥ 75,000/µl
    3. PT/INR and PTT ≤ 1.5 x ULN
    4. Bilirubin ≤ 2.0 x ULN
    5. Creatinine ≤ 1.5 x ULN
    6. ALT/AST ≤ 5 x ULN (subjects with liver metastases) or ALT/AST ≤ 2.5 x ULN (subjects without liver metastases)
    7. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen > 92% on room air
    8. Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO/MUGA
  7. Provides written informed consent.
  8. Subjects of reproductive potential must agree to use acceptable birth control methods, as described in the protocol

Exclusion Criteria:

  1. Patients with known CNS metastases
  2. Active invasive cancer other than the one of the two cancers targeted by this study. Patients with active non-invasive cancers (such as non-melanoma skin cancer, superficial cervical and bladder and prostate cancer with PSA level < 1.0) are not excluded.
  3. Active hepatitis B or hepatitis C infection.
  4. Chronic hepatitis C with a FibroScan score equivalent to fibrosis stage 2 (F2) or greater.
  5. Patients with known cirrhosis.
  6. Patients with ongoing or active infection.
  7. Patients with a known history of Li Fraumeni syndrome or retinoblastoma protein pathway germinal deficiency.
  8. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10 mg of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded.
  9. Planned concurrent treatment with systemic high dose corticosteroids. Patients may be on a stable low dose of steroids (≤ 10mg equivalent of prednisone). Use of inhaled steroids is allowable.
  10. Patients requiring supplemental oxygen therapy.
  11. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).
  12. Any clinically significant pericardial effusion, Class II-IV cardiovascular disability according to the New York Heart Association Classification (see Appendix 4) or other cardiovascular condition that would preclude assessment of mesothelin induced pericarditis or that may worsen as a result of toxicities expected for this study. This determination will be made by a cardiologist if cardiac issues are suspected.
  13. Pregnant or breastfeeding women.
  14. Treatment with a PD-1 or PD-L1 inhibitor, including but not limited to nivolumab, pembrolizumab, atezolizumab, and/or durvalumab, within 2 months prior to eligibility confirmation by a physician-investigator.
  15. Patients with significant lung disease as follows:

    1. Patients with radiographic evidence of greater than lobar lymphangitic pulmonary involvement, greater than lobar bronchial wall thickening suggestive of peribronchial lymphatic disease extension, and/or evidence of extensive bilateral parenchymal metastatic burden.
    2. Patients with radiographic and/or clinical evidence of active radiation pneumonitis.
    3. Patients with radiographic evidence of underlying interstitial lung disease, including evidence of unresolved drug toxicity from any agent (e.g. chemotherapy, targeted agents, amiodarone, nitrofurantoin, etc.)

Sites / Locations

  • University of PennsylvaniaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

Cohort 1

Cohort 2

Cohort -1

Arm Description

Single dose of 3.3x10(12) vp of VCN-01 on Day 0, followed by a single dose of 5x10(7) of huCART-meso cells on Day 14.

Single dose of 1x10(13) vp of VCN-01 on Day 0, followed by a single dose of 5x10(7) of huCART-meso cells on Day 14.

In the event that 2 DLTs occur in Cohort 1, then enrollment in Cohort 1 will be stopped and Cohort -1 will be opened for evaluation. Enrolled subjects will receive a single dose of huCART-meso cells on Day 0 followed by a single dose of 3.3x10(12) vp of VCN-01 on Day 14.

Outcomes

Primary Outcome Measures

Type, frequency, severity, and attribution of AEs/SAEs as assessed by CTCAE v 5.0
Occurrence of dose-limiting toxicities.

Secondary Outcome Measures

Proportion of subjects enrolled who receive one or both of the intended study infusions
Overall Response Rate (ORR)
Best Overall Response (BOR)
Duration of Response (DOR)
Progression Free Survival (PFS)
Overall Survival (OS)

Full Information

First Posted
September 15, 2021
Last Updated
June 20, 2023
Sponsor
University of Pennsylvania
Collaborators
Theriva Biologics SL
search

1. Study Identification

Unique Protocol Identification Number
NCT05057715
Brief Title
huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
Official Title
Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 2, 2022 (Actual)
Primary Completion Date
September 2038 (Anticipated)
Study Completion Date
September 2038 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Pennsylvania
Collaborators
Theriva Biologics SL

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Phase I study evaluating the safety and feasibility of lentiviral transduced huCART-meso cells when given in combination with VCN-01 in a 3+3 dose (de)escalation design.
Detailed Description
This is a Phase I study evaluating the safety and feasibility of lentiviral transduced huCART-meso cells when given in combination with VCN-01 in a 3+3 dose (de)escalation design as follows: Cohort 1 (N = 3-6): will receive VCN-01 as a single IV infusion of 3.3x1012 vp on Day 0, followed by a single dose of 5x107 huCART-meso cells on Day 14 via IV infusion. This cohort will be evaluated as follows: If 1 DLT/3 subjects occurs, Cohort 1 will be expanded to enroll an additional 3 evaluable subjects. If 0 DLT/3 subjects or 1 DLT/6 subjects, the study will advance to Cohort 2. Cohort 2 (N = 3-6): will receive VCN-01 as a single IV infusion of 1x1013 vp on Day 0 followed by a single dose of 5x107 cells huCART-meso cells on Day 14 via IV infusion. This cohort will be evaluated as follows: If 0 DLT/3 subjects or 1 DLT/3 subjects occurs, Cohort 2 will be expanded to enroll an additional 3 evaluable subjects. If 0 DLT/6 subjects or 1 DLT/6 subjects occurs, this dose combination will be identified as the recommended phase 2 dose (RP2D). If 2 DLTs occur at any time, enrollment in this Cohort will be stopped. If less than 6 subjects were infused in Cohort 1 prior to Cohort 2 escalation, additional subjects will be enrolled in Cohort 1to reach a minimum of 6 evaluable subjects. In the event that 2 DLTs occur in Cohort 1, then enrollment in Cohort 1 will be stopped and Cohort -1 will be opened for evaluation. Cohort -1 will evaluate a different sequence of administration for these two investigational products at the same dose level used in Cohort 1. • Cohort -1 (N = up to 6): will receive a single dose of 5x107 huCART-meso cells via IV infusions on Day 0 followed by VCN-01 as a single infusion of 3.3x1012 vp on Day 10. Up to 6 subjects will be infused in Cohort -1 unless > 1 DLTs are observed at any time. The Day 0 infusions of the first two subjects in each cohort will be staggered by at least 42 days from the prior subject's 1st infusion (huCART-meso or VCN-01; depending on the cohort assignment), to allow for the assessment of DLTs and a formal decision regarding cohort progression, expansion, or de-escalation. Subsequent subject infusions within that cohort will be staggered by at least 14 days from the preceding subject's second infusion. Formal DLT assessments will be performed by the Clinical PI and Sponsor Medical Director in accordance with the definition provided in the protocol.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Cancer, Serous Ovarian Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
3+3
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
12 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1
Arm Type
Active Comparator
Arm Description
Single dose of 3.3x10(12) vp of VCN-01 on Day 0, followed by a single dose of 5x10(7) of huCART-meso cells on Day 14.
Arm Title
Cohort 2
Arm Type
Active Comparator
Arm Description
Single dose of 1x10(13) vp of VCN-01 on Day 0, followed by a single dose of 5x10(7) of huCART-meso cells on Day 14.
Arm Title
Cohort -1
Arm Type
Active Comparator
Arm Description
In the event that 2 DLTs occur in Cohort 1, then enrollment in Cohort 1 will be stopped and Cohort -1 will be opened for evaluation. Enrolled subjects will receive a single dose of huCART-meso cells on Day 0 followed by a single dose of 3.3x10(12) vp of VCN-01 on Day 14.
Intervention Type
Biological
Intervention Name(s)
VCN-01
Intervention Description
Intravenous administration of VCN-01
Intervention Type
Biological
Intervention Name(s)
huCART-meso Cells
Intervention Description
Intravenous administration of huCART-meso cells
Primary Outcome Measure Information:
Title
Type, frequency, severity, and attribution of AEs/SAEs as assessed by CTCAE v 5.0
Time Frame
2 years
Title
Occurrence of dose-limiting toxicities.
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Proportion of subjects enrolled who receive one or both of the intended study infusions
Time Frame
2 years
Title
Overall Response Rate (ORR)
Time Frame
15 years
Title
Best Overall Response (BOR)
Time Frame
15 years
Title
Duration of Response (DOR)
Time Frame
15 years
Title
Progression Free Survival (PFS)
Time Frame
15 years
Title
Overall Survival (OS)
Time Frame
15 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with one of the following diagnoses: Histologically confirmed unresectable or metastatic pancreatic adenocarcinoma; OR Persistent or recurrent serous epithelial ovarian cancer Progression or intolerance to at least one prior standard of care chemotherapy for advanced stage disease. Subjects must have measurable disease as defined by RECIST 1.1 criteria. Patients ≥ 18 years of age. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Adequate organ and bone marrow function defined as: Hemoglobin ≥ 9 g/dL Platelets ≥ 75,000/µl PT/INR and PTT ≤ 1.5 x ULN Bilirubin ≤ 2.0 x ULN Creatinine ≤ 1.5 x ULN ALT/AST ≤ 5 x ULN (subjects with liver metastases) or ALT/AST ≤ 2.5 x ULN (subjects without liver metastases) Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen > 92% on room air Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO/MUGA Provides written informed consent. Subjects of reproductive potential must agree to use acceptable birth control methods, as described in the protocol Exclusion Criteria: Patients with known CNS metastases Active invasive cancer other than the one of the two cancers targeted by this study. Patients with active non-invasive cancers (such as non-melanoma skin cancer, superficial cervical and bladder and prostate cancer with PSA level < 1.0) are not excluded. Active hepatitis B or hepatitis C infection. Chronic hepatitis C with a FibroScan score equivalent to fibrosis stage 2 (F2) or greater. Patients with known cirrhosis. Patients with ongoing or active infection. Patients with a known history of Li Fraumeni syndrome or retinoblastoma protein pathway germinal deficiency. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10 mg of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded. Planned concurrent treatment with systemic high dose corticosteroids. Patients may be on a stable low dose of steroids (≤ 10mg equivalent of prednisone). Use of inhaled steroids is allowable. Patients requiring supplemental oxygen therapy. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40). Any clinically significant pericardial effusion, Class II-IV cardiovascular disability according to the New York Heart Association Classification (see Appendix 4) or other cardiovascular condition that would preclude assessment of mesothelin induced pericarditis or that may worsen as a result of toxicities expected for this study. This determination will be made by a cardiologist if cardiac issues are suspected. Pregnant or breastfeeding women. Treatment with a PD-1 or PD-L1 inhibitor, including but not limited to nivolumab, pembrolizumab, atezolizumab, and/or durvalumab, within 2 months prior to eligibility confirmation by a physician-investigator. Patients with significant lung disease as follows: Patients with radiographic evidence of greater than lobar lymphangitic pulmonary involvement, greater than lobar bronchial wall thickening suggestive of peribronchial lymphatic disease extension, and/or evidence of extensive bilateral parenchymal metastatic burden. Patients with radiographic and/or clinical evidence of active radiation pneumonitis. Patients with radiographic evidence of underlying interstitial lung disease, including evidence of unresolved drug toxicity from any agent (e.g. chemotherapy, targeted agents, amiodarone, nitrofurantoin, etc.)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Abramson Cancer Center Clinical Trials Services
Phone
855-216-0098
Email
PennCancerTrials@careboxhealth.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Janos L. Tanyi, MD, PhD
Organizational Affiliation
University of Pennsylvania
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Abramson Cancer Center Clinical Trials Service
Phone
855-216-0098
Email
PennCancerTrials@careboxhealth.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

We'll reach out to this number within 24 hrs